September 2026 Research Update

This month brought an early but concrete step toward finding possible treatments by testing many existing medicines directly in human nerve cells grown from children with MPS IIIA. In this lab work, multiple drugs moved diseased cells toward a more healthy-like state across several kinds of measurements, including cell health, stored material related to the disorder, and how nerve cells communicate. The results do not show what will happen in people, but they help narrow down which drug ideas look most promising for follow-up testing. [1]

Researchers grew cortical neurons from patient-derived stem cells (from five children with MPS IIIA) and compared them with neurons made from matched controls, then screened 63 FDA-approved drugs. At least nine drugs were reported to significantly lessen disease-related features within about 2 weeks, including acetyl-D-leucine, allopurinol, probenecid, lumiracoxib, ketorolac, lithium, theophylline, desferrioxamine, and hydroxychloroquine. Some drugs tested caused notable cell death in the dish and were removed from further analysis, which highlights that not every repurposed drug will be tolerated even at the lab level. [1]

Several of the drugs were linked with reductions in markers connected to how MPS IIIA affects cells, such as enlarged lysosomes and excess heparan sulfate inside and outside cells. The same experiments also tracked signs of nerve cell stress and support-cell (astrocyte) activation, and the drug signals were supported by imaging analysis and gene activity readouts that shifted toward control-like patterns. This matters because it suggests the drug effects were not limited to a single test, but appeared across different ways of looking at cell function. [1]

One notable finding was that a four-drug combination (allopurinol, probenecid, acetyl-D-leucine, and theophylline) was reported to restore balance between excitatory and inhibitory signaling and reduce network hyperactivity, with effects that lasted after treatment stopped in the dish. The study also reported gene-expression changes consistent with partial rescue of dysregulated neuronal pathways and changes in immune/inflammatory pathways in astrocytes. These details are still laboratory observations, but they give specific, testable targets for the next stage of research. [1]

For families, this is mainly early research that may matter later rather than something that changes care now. The study helps clarify that patient-derived neurons can be used to rapidly compare many existing drugs side-by-side, and it points to a short list of candidates and one combination that looked especially promising in cell tests. What remains uncertain is whether any of these drugs, alone or in combination, would be safe or helpful in children with MPS IIIA, since the work did not include animal or human testing and did not explore different doses. [1]

This kind of work can still be meaningful for patients because it provides a clearer roadmap for what researchers might test next, using models built from affected children rather than relying only on animal models or single measurements. It also shows that some drugs can look helpful on certain lab readouts while others can be harmful to cells, which supports the need for careful step-by-step validation. If follow-up studies confirm these signals in animals and then in clinical research, the most promising candidates could become priorities for future trials, but that next evidence is not available yet. [1]